TY - JOUR
T1 - Synergistic opportunities in the interplay between cancer screening and cardiovascular disease risk assessment
T2 - Together we are stronger
AU - Handy, Catherine E.
AU - Quispe, Renato
AU - Pinto, Xavier
AU - Blaha, Michael J.
AU - Blumenthal, Roger S.
AU - Michos, Erin D.
AU - Lima, Joao A.C.
AU - Guallar, Eliseo
AU - Ryu, Seungho
AU - Cho, Juhee
AU - Kaye, James A.
AU - Comin-Colet, Josep
AU - Corbella, Xavier
AU - Cainzos-Achirica, Miguel
N1 - Funding Information:
Dr Handy received research support from the Conquer Cancer Foundation/ Bristol-Meyers Squibb.
Funding Information:
Dr Kaye is a full-time employee of Research Triangle Institute Health Solutions, an independent nonprofit research organization which has received funding from Novartis and other pharmaceutical companies. Dr Blaha has served on an Advisory Board for Novartis. Dr Cainzos-Achirica collaborates with Research Triangle Institute Health Solutions, an independent nonprofit research organization that has received funding from Novartis and other pharmaceutical companies. The other authors report no conflicts.
Publisher Copyright:
© 2018 American Heart Association, Inc.
PY - 2018
Y1 - 2018
N2 - Cardiovascular disease (CVD) and cancer continue to be the 2 leading causes of death in developed countries despite significant improvements in the prevention, screening, and treatment of both diseases. They remain significant public health problems, growing in importance globally. Despite this threat, the fields of cardiology and oncology have been relatively disconnected. With many shared modifiable risk factors, cancer and CVD often coexist in the same individuals; those diagnosed with lung cancer, breast cancer, and colon cancer are at higher risk of CVD, and those with CVD are at higher risk of developing many types of common cancers. Screening paradigms have been established in parallel, but there are opportunities for combined risk assessments for cancer and CVD risk. Joining forces for combined cardiovascular and hemato-oncological preventive and research efforts will likely have synergistic, worldwide public health benefits.
AB - Cardiovascular disease (CVD) and cancer continue to be the 2 leading causes of death in developed countries despite significant improvements in the prevention, screening, and treatment of both diseases. They remain significant public health problems, growing in importance globally. Despite this threat, the fields of cardiology and oncology have been relatively disconnected. With many shared modifiable risk factors, cancer and CVD often coexist in the same individuals; those diagnosed with lung cancer, breast cancer, and colon cancer are at higher risk of CVD, and those with CVD are at higher risk of developing many types of common cancers. Screening paradigms have been established in parallel, but there are opportunities for combined risk assessments for cancer and CVD risk. Joining forces for combined cardiovascular and hemato-oncological preventive and research efforts will likely have synergistic, worldwide public health benefits.
KW - Cancer
KW - Cardiovascular diseases
KW - Prevention
KW - Screening
UR - http://www.scopus.com/inward/record.url?scp=85055647713&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85055647713&partnerID=8YFLogxK
U2 - 10.1161/CIRCULATIONAHA.118.035516
DO - 10.1161/CIRCULATIONAHA.118.035516
M3 - Article
C2 - 30359131
AN - SCOPUS:85055647713
SN - 0009-7322
VL - 138
SP - 727
EP - 734
JO - Circulation
JF - Circulation
IS - 7
ER -